S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:CNCEConcert Pharmaceuticals Stock Price, Forecast & News

$10.17
-0.02 (-0.20 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.98
Now: $10.17
$10.20
50-Day Range
$8.67
MA: $9.88
$11.52
52-Week Range
$5.36
Now: $10.17
$13.09
Volume1,950 shs
Average Volume164,003 shs
Market Capitalization$301.83 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
Concert Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 million
Book Value$4.26 per share

Profitability

Net Income$-78,170,000.00
Net Margins-1,108.62%

Miscellaneous

Employees71
Market Cap$301.83 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$10.17
-0.02 (-0.20 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

How has Concert Pharmaceuticals' stock price been impacted by COVID-19?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNCE stock has increased by 21.8% and is now trading at $10.17.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Concert Pharmaceuticals
.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Concert Pharmaceuticals
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.28. Concert Pharmaceuticals had a negative return on equity of 56.88% and a negative net margin of 1,108.62%.
View Concert Pharmaceuticals' earnings history
.

What price target have analysts set for CNCE?

7 analysts have issued twelve-month price objectives for Concert Pharmaceuticals' stock. Their forecasts range from $10.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 91.7% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals
.

Has Concert Pharmaceuticals been receiving favorable news coverage?

Media headlines about CNCE stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Concert Pharmaceuticals earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Concert Pharmaceuticals
.

Are investors shorting Concert Pharmaceuticals?

Concert Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 766,200 shares, an increase of 27.6% from the June 15th total of 600,600 shares. Based on an average trading volume of 146,600 shares, the short-interest ratio is currently 5.2 days.
View Concert Pharmaceuticals' Short Interest
.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger Biopharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Amicus Therapeutics (FOLD), Intel (INTC), Nektar Therapeutics (NKTR), Inovio Pharmaceuticals (INO), Mallinckrodt (MNK) and Aerie Pharmaceuticals (AERI).

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of America Corp DE (6.29%), Ingalls & Snyder LLC (4.66%), Alyeska Investment Group L.P. (1.69%), Prudential Financial Inc. (1.04%), Point72 Asset Management L.P. (0.62%) and Russell Investments Group Ltd. (0.58%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals
.

Which institutional investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Goldman Sachs Group Inc., Prudential Financial Inc., California Public Employees Retirement System, Alps Advisors Inc., UBS Group AG, and WINTON GROUP Ltd.
View insider buying and selling activity for Concert Pharmaceuticals
.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Alyeska Investment Group L.P., Bessemer Group Inc., Dupont Capital Management Corp, Russell Investments Group Ltd., SG Americas Securities LLC, Hancock Whitney Corp, and Steward Partners Investment Advisory LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich, and Thomas G Auchincloss.
View insider buying and selling activity for Concert Pharmaceuticals
.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $10.17.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $301.83 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.